Login / Signup

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.

Elma AflakiDaniel K BorgerNima MoavenBarbara K StubblefieldSteven A RogersSamarjit PatnaikFrank J SchoenenWendy WestbroekWei ZhengPatricia SullivanHideji FujiwaraRohini SidhuZayd M KhaliqGrisel J LopezDavid S GoldsteinDaniel S OryJuan MaruganEllen Sidransky
Published in: The Journal of neuroscience : the official journal of the Society for Neuroscience (2017)
Because GBA1 mutations are the most common genetic risk factor for Parkinson disease, dopaminergic neurons were generated from iPSC lines derived from patients with Gaucher disease with and without parkinsonism. These cells exhibit deficient enzymatic activity, reduced lysosomal glucocerebrosidase levels, and storage of glucosylceramide and glucosylsphingosine. Lines generated from the patients with parkinsonism demonstrated elevated levels of α-synuclein. To reverse the observed phenotype, the neurons were treated with a novel noninhibitory glucocerebrosidase chaperone, which successfully restored glucocerebrosidase activity and protein levels and reduced glycolipid storage. In addition, the small-molecule chaperone reduced α-synuclein levels in dopaminergic neurons, indicating that chaperoning glucocerebrosidase to the lysosome may provide a novel therapeutic strategy for both Parkinson disease and neuronopathic forms of Gaucher disease.
Keyphrases